Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Net Margin (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 6 years of Net Margin data on record, last reported at 114.97% in Q3 2025.

  • For Q3 2025, Net Margin rose 46647.0% year-over-year to 114.97%; the TTM value through Sep 2025 reached 127.25%, up 45419.0%, while the annual FY2022 figure was 8697.64%, 729747.0% down from the prior year.
  • Net Margin reached 114.97% in Q3 2025 per CYCN's latest filing, up from 1797.85% in the prior quarter.
  • Across five years, Net Margin topped out at 627.5% in Q3 2022 and bottomed at 21604.84% in Q1 2021.
  • Average Net Margin over 4 years is 3161.68%, with a median of 1798.31% recorded in 2025.
  • Peak YoY movement for Net Margin: tumbled -1960997bps in 2021, then skyrocketed 1977868bps in 2022.
  • A 4-year view of Net Margin shows it stood at 2690.24% in 2021, then soared by 123bps to 627.5% in 2022, then crashed by -96bps to 27.8% in 2024, then plummeted by -514bps to 114.97% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 114.97% in Q3 2025, 1797.85% in Q2 2025, and 1798.77% in Q1 2025.